Back to today’s briefing

Story perspectives

Pfizer to Acquire Metsera for $7.3 Billion, Expands Obesity Portfolio

9/23/2025

26 5 Full Breakdown

Summary

Pfizer Expands Obesity Portfolio

Pfizer will acquire Metsera for up to $7.3 billion, at $47.50 per share in cash plus milestone payments; closing in 2025.
The deal expands Pfizer's obesity portfolio as the market is projected to reach $150 billion by the early 2030s.
Metsera's MET-097i shows 11.3% weight loss in trials and is a once-monthly injection.
Pfizer abandoned danuglipron due to safety concerns.

History

Historical Context

The obesity drug market was valued at $2.1 billion in 2015, with Novo Nordisk as a key player. Pfizer's acquisition of Medivation for $14 billion in 2016, following its abandonment of danuglipron due to safety issues, reflects the competitive landscape in obesity treatments. This strategic move positions Pfizer to influence future drug development in a projected $150 billion market by the early 2030s.

1 of 2

Pfizer Expands Obesity Portfolio

Pfizer will acquire Metsera for up to $7.3 billion, at $47.50 per share in cash plus milestone payments; closing in 2025.
The deal expands Pfizer's obesity portfolio as the market is projected to reach $150 billion by the early 2030s.
Metsera's MET-097i shows 11.3% weight loss in trials and is a once-monthly injection.
Pfizer abandoned danuglipron due to safety concerns.

1 / 2